pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights
The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks.
Highlights of the pCPA activity in March are:
- 5 products completed CADTH review, for a total of 16 files under consideration;
- 2 products initiated pCPA negotiations, for a total of 29 active negotiations;
- 3 negotiations completed for a total of 304 completed negotiations;
- 3 negotiations closed, for a total of 51 closed negotiations; and
- No files were closed without negotiation, for a total of 73 declined negotiations.
Files Under pCPA Consideration
5 new drug products received a CDEC recommendation or pERC notification to implement in March 2020, for a total of 16 products under pCPA Consideration.
|Brand Name||Generic Name||Manufacturer||Indication||Recommendation|
|Lokelma||sodium zirconium cyclosilicate||AstraZeneca||Hyperkalemia, adults||Do not reimburse|
|Monoferric||Iron (III) Isomaltoside 1000||Pharmacosmos A/S||Iron deficiency anemia||Conditional|
|Onstryv||Safinamide||Valeo||Parkinson’s disease||Do not reimburse|
|Taltz||ixekizumab||Eli Lilly||Ankylosing spondylitis||Conditional|
The pCPA initiated 2 new negotiations in March, for a total of 29 active negotiations.
|Brand Name||Generic Name||Manufacturer||Indication||CADTH Date||Initiation||Time to Initiate|
|Kanjinti||Trastuzumab||Amgen||early breast cancer/metastatic breast cancer/metastatic gastric cancer||N/A||24 Mar 20||N/A|
|Envarsus PA||Tacrolimus||Paladin||prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients||N/A||16 Mar 20||N/A|
March saw the pCPA initiate negotiations for the 4th trastuzumab biosimilar (Kanjinti), while Envarsus enters pCPA negotiations after being reviewed by INESSS; recommendation issued November 2019.
The pCPA completed 3 negotiations since the last update for a total of 304 completed negotiations.
|Brand Name||Generic Name||Manufacturer||Indication||Initiation||Close Date||Duration|
|Triamcinolone Hexacetonide||Triamcinolone Hexacetonide||Medexus||Rheumatoid Arthritis||22 Nov 19||31 Mar 20||130 days|
|Xalkori||Crizotinib||Pfizer||ROS1-positive advanced NSCLC||27 Aug 19||20 Mar 20||206 days|
|Januvia||Sitagliptin||Merck||Diabetes mellitus, Type 2||2 Nov 18||10 Mar 20||494 days|
The pCPA and Merck have renegotiated the Januvia agreement, after over 16 months of discussions.
The pCPA closed 3 negotiations since the last update for a total of 51 closed negotiations.
|Brand Name||Generic Name||Manufacturer||Indication||Engagement Letter||Close Date||Duration|
|Orfadin Oral Suspension||nitisinone||Sobi||Hereditary Tyrosinemia Type 1||August 9, 2019||March 30, 2020||234 days|
|Steglatro||ertugliflozin||Merck||Diabetes Mellitus, Type 2||March 20, 2019||March 31, 2020||377 days|
|Segluromet||ertugliflozin and metformin hydrochloride||Merck||Diabetes Mellitus, Type 2||March 20, 2019||March 31, 2020||377 days|